RT @drdavidliew: Malignancy in real world datasets: do we see differences between DMARDs - particularly JAKi, with ORAL
Tweet Content
Malignancy in real world datasets:
do we see differences between DMARDs - particularly JAKi, with ORAL Surveillance in mind?
RABBIT German data (limited risk window):
Point estimates slightly up vs TNFi, esp in high CV risk pts
but magnitude not big
OP0218 #EULAR2023 @RheumNow https://t.co/Ou7TgWvf3b
Show on Archive Page
On
Display in Search Results
On
PDQ
Off